Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Ticker
Market factors today
Unlock the full PLYX picture
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
PLYX stock facts
| Ticker symbol | PLYX |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $104.2M |
| CEO | Alex Yang |
| Employees | 11 |
| Headquarters | Paramus, NJ, US |
| IPO date | 2026-02-02 |
| Website | polaryx.com |
What you can see for PLYX on Tickr
Live PLYX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PLYX report.
Rankings
FAQ
What is the ticker symbol for Polaryx Therapeutics, Inc. Common Stock?
The ticker symbol for Polaryx Therapeutics, Inc. Common Stock is PLYX, listed on the NASDAQ Global Market.
What is PLYX?
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a…